Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05722405 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 5, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University to Second Affiliated Hospital, Zhejiang University, School of Medicine
  2. Primary completion date: Jun 30, 2024 to Jun 30, 2026
    • Study completion date: Jul 31, 2025 to Jul 31, 2028
    • Study description expanded, about 39 words
    • Collaborators revised (7)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.
Trial Details
NCT Number NCT05722405
Lead Sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine
Collaborators: Affiliated Hospital of Jiaxing University, Huzhou Central Hospital, Lishui Country People's Hospital, Dongyang People's Hospital, Shangyu People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov